Ovid Therapeutics Inc. (OVID): Total Liabilities
$20.27M
As of 2025-12-31
$22.08M
As of 2026-06-30
-4.1%
3-year compound annual growth
-8.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $20.27M | -15.3% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $23.94M | -57.4% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $56.23M | +144.6% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $22.99M | +55.4% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $14.80M | -54.2% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $32.29M | +198.5% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $10.82M | +22.3% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $8.84M | n/a | 2020-03-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $51.40M | +18.9% |
| Immunome Inc. (IMNM) | 2025-12-31 | $48.84M | -17.3% |
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $62.07M | -5.7% |
Compare OVID, WHWK, XENE, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗